IFEMEndo Endometriosis Center

IFEMEndo Endometriosis Center

Top Expertise for Women's Health


The IFEM Endo Medicover Cluj Endometriosis Center was established out of the need to provide patients with access to accurate diagnosis and personalized treatment based on the latest medical standards. Created in partnership with the IFEM Endo Institute, this center represents a first in the region, bringing together a multidisciplinary team of specialists dedicated to the integrated management of endometriosis.


Through the collaboration between Medicover Hospital Cluj and the IFEM Endo Institute, patients benefit from advanced technologies, internationally recognized expertise, and an individualized approach designed to improve the quality of life of women affected by this complex condition.


Request an Appointment

Appointments are made exclusively through the call center! After scheduling, please download and send the completed questionnaire to the email address: ifemendocluj@medicover.ro!



The Center's Mission

The Endometriosis Center of Medicover Hospital Cluj, in partnership with IFEM Endo, has the mission of providing excellent medical care to women diagnosed with endometriosis through a multidisciplinary, minimally invasive, and personalized approach. We are dedicated to improving patients' quality of life through accurate diagnosis, innovative treatments, and long-term support based on the latest international guidelines.


About Endometriosis

Endometriosis is a chronic disease in which tissue resembling endometrium is found outside the uterus.

These fragments are located inside the abdominal cavity, where they can graft onto the peritoneum, a thin membrane covering all intra-abdominal organs (peritoneal or superficial endometriosis), or beyond this membrane, deeply infiltrating various organs or anatomical structures (subperitoneal/deep infiltrating endometriosis).

These tissue fragments, known as "endometriotic lesions," vary in size (from a few tens of microns to several centimeters) and have the potential to grow and spread via foci that flare synchronously with menstruation.


What is the endometrium?


Causes of Endometriosis


Consequences of Endometriotic Lesions


Types of Endometriosis

From a didactic standpoint, endometriotic lesions are classified into 3 major groups, which may coexist in the same woman. Theoretically, endometriotic lesions can be found anywhere in the pelvis and abdomen and, more rarely, in the thorax.


  1. Superficial peritoneal lesions are likely the most common and are localized on the peritoneum.

These are small, superficial lesions whose invasion depth does not exceed 5 mm.

They can present in various forms:

  • Sometimes, they are active, red lesions, closely resembling endometrium, often hemorrhagic, surrounded by an inflammatory reaction (a);

  • Other lesions have a brownish appearance (b), or appear as black microcysts (c), indicating old hemorrhage;

  • Others are whitish and fibrotic, indicating a healing or cicatricial process (d).


  1. Cystic ovarian lesions (ovarian endometriomas)

These are hemorrhagic lesions that develop beneath the ovarian parenchyma and progressively displace it. Ranging in size from a few millimeters to several centimeters, these lesions are not true intra-ovarian cysts like other types of ovarian cysts. They are the result of intra-ovarian invagination of a lesion initially located on the ovarian surface, which gradually invaginates into the ovary. This characteristic makes surgical management difficult, as the endometrioma wall and the ovarian tissue are sometimes inseparable, which can lead to ovarian damage during cystectomy.


  1. Deep subperitoneal lesions (infiltration greater than 5 mm)

These are firm, fibrous lesions in which hormone-dependent endometrial tissue accounts for a relatively small proportion (15-20% of the endometriotic nodule volume). These lesions tend to infiltrate surrounding organs, behaving aggressively like tumors, resulting in severe presentations that become increasingly difficult to resect. Due to their fibrous composition, which is poorly hormone-dependent, the size of deep endometriotic nodules is minimally influenced by amenorrhea, which only stabilizes the disease but practically never causes it to regress completely. This explains why they can be found in postmenopausal women, where they may remain symptomatic despite definitive amenorrhea.


Symptoms of Endometriosis

Endometriotic lesions are responsible for a wide range of painful symptoms that initially occur during menstruation. Over the years, these symptoms may also present outside menses, though their severity remains highest during or around menstruation. Classic symptoms include lower abdominal pain (pelvic pain), deep pelvic pain during sexual intercourse (dyspareunia), pain with bowel movements (dyschezia) or urination (dysuria), chest or shoulder pain, and sciatica-type radiating pain. Endometriosis can also lead to infertility. This infertility, combined with the painful symptoms described above, justifies screening for endometriosis.


Dysmenorrhea (Painful Menstruation)


Deep Dyspareunia or Pain During Intercourse


Gastrointestinal symptoms associated with menstruation are varied and nonspecific


Urinary Symptoms


Other Catamenial Symptoms


Intermenstrual Pain


Infertility


Endometriosis Symptoms in Numbers

40%

of women suffering from infertility

and chronic pain have endometriosis

48%

report that their sexual life is impaired by the disease

45%

believe their professional career

has been adversely affected by this condition



  • Diagnosis of Endometriosis

The diagnosis of endometriosis is primarily clinical. An experienced practitioner can make the diagnosis in most cases well before performing imaging studies, guided by thorough clinical history-taking and a meticulous, focused physical examination.

The purpose of complementary examinations is to evaluate disease severity (staging/mapping of lesions) and to guide appropriate treatment planning. These must be performed by radiologists and sonographers experienced in endometriosis. Normal imaging does not rule out the diagnosis, especially in cases of superficial peritoneal endometriosis.


  • The Consultation

This is fundamental and often sufficient to establish clinical suspicion. The objective is to correlate the timeline of painful symptoms with the menstrual cycle. It must also screen for the symptoms mentioned above (pelvic pain, dyspareunia, gastrointestinal and urinary symptoms, etc.).


  • Abdominal Examination

Generally causes nonspecific tenderness (pain upon palpation of the colon frame or pelvis). However, when performed during an acute pain flare, it can mimic an acute surgical abdomen. In addition, rare complications can truly cause an acute surgical abdomen (bowel obstruction, renal colic).


  • Speculum Examination

Must be performed gently, as contact with the vaginal fornices is often painful. It is frequently normal, but may reveal a deep infiltrating nodule involving the posterior vaginal fornix, visible as a bluish/black microcystic lesion or fibrotic retraction.


  • Bimanual Vaginal Examination

It is essential, as it can confirm the presence of deep endometriosis, though it cannot be performed in virginal patients. Findings sought upon palpation include:

  • A soft but tender posterior vaginal fornix, which may indicate superficial endometriosis of the pouch of Douglas;

  • A palpable, tender nodule or induration in the vaginal fornices, indicative of deep infiltrating endometriosis;

  • An enlarged, globally tender uterus suggestive of adenomyosis;

  • A cystic adnexal mass suggestive of an ovarian endometrioma.


  • Digital Rectal Examination

It is particularly useful when deep retrocervical endometriosis is suspected and can be used to evaluate infiltration of the anterior rectal wall or parametria.


Paraclinical Examinations


  • Transvaginal Pelvic Ultrasound

Ultrasound is considered the first-line imaging modality and is highly accurate in the hands of an experienced radiologist or gynecologist. It can identify:

  • Ovarian endometriomas;

  • Adenomyosis;

  • Deep infiltrating endometriosis nodules in the uterosacral ligaments, bladder, rectum, and distal sigmoid colon;

  • Pelvic cystic collections, such as dilated fallopian tubes filled with blood (hematosalpinx), peritoneal pseudocysts resulting from adhesions, etc.


  • Abdominal Ultrasound

Can be used to detect complications of endometriosis, such as ureteral stenosis with hydronephrosis, renal atrophy, or extensive intra-abdominal endometriosis with ascites formation, etc.


  • Magnetic Resonance Imaging (MRI)

Pelvic MRI is an exceptional diagnostic modality that allows not only diagnosis but also precise anatomical mapping of intrapelvic and intra-abdominal endometriotic lesions. In our practice, it is virtually indispensable prior to surgical intervention and allows detection of:

  • Ovarian endometriomas containing blood products, which display characteristic hyperintensity on T1-weighted fat-saturated sequences and hypointensity on T2-weighted sequences ("T2 shading");

  • Deep endometriotic nodules presenting as stellate (hypointense on T1 and T2), retractile tissue infiltrating adjacent organs (rectum, sigmoid colon, vagina, bladder, etc.), sometimes containing hemorrhagic microcysts;

  • Adenomyosis, confirmed by junctional zone thickening or multiple myometrial hyperintense microspots;

  • Complications of endometriosis (hematosalpinx, ureteral stenosis with hydronephrosis, infiltration of parametria or sacral roots, digestive tract stenosis, etc.).


Other investigations may be indicated in severe cases, depending on the anatomical sites of endometriotic lesions identified on ultrasound and MRI.


These include endorectal ultrasound and CT colonography in cases of colorectal endometriosis, cystoscopy, CT urography or MR urography in urinary tract involvement, and MRI and/or CT of the diaphragm for diaphragmatic endometriosis. No serum biomarker is disease-specific. Elevated CA-125 may be observed in cases of ovarian or extensive peritoneal endometriosis, but this non-specific test is not routinely indicated.


Currently, research is ongoing to identify serum biomarkers that could reliably detect whether a woman has endometriosis via a simple blood test.


  • Laparoscopy

If necessary, a definitive histopathological diagnosis can be obtained by exploratory laparoscopy combined with targeted biopsy and pathological examination.


In cases of infertility, it can be used to stage prognosis according to the rASRM classification (revised American Society for Reproductive Medicine) and, when appropriate, treat superficial lesions.


However, diagnostic laparoscopy is not mandatory to initiate medical therapy in patients where endometriosis is strongly suspected on clinical examination and non-invasive imaging. It should be reserved for cases with diagnostic uncertainty and is not recommended solely to confirm conclusive imaging findings.


Today, laparoscopy is primarily reserved for therapeutic surgical management of endometriotic lesions.



  • Saliva Test

A major breakthrough in the field of endometriosis has been the introduction, in 2022, of a salivary biomarker test for endometriosis. Developed based on the scientific research of Professor Bendifallah and manufactured by the French biotech company ZIWIG, this saliva test boasts high diagnostic sensitivity and specificity, enabling the distinction between women with and without endometriosis with a low error rate.


The test identifies an expression signature composed of 109 microRNAs, developed through the combination of next-generation sequencing and artificial intelligence, and was evaluated in two prospective clinical studies (monocentric and multicentric). This diagnostic tool is promising and paves the way for advanced non-invasive testing capable of predicting specific endometriosis subtypes, allowing personalized therapeutic and monitoring strategies tailored to the progressive risk of each phenotype, similar to paradigms established in breast oncology.


The exact clinical positioning of the saliva test relative to imaging modalities has yet to be definitively formalized by the French National Authority for Health (HAS), though reimbursement coverage by the French health insurance system (CPAM) is undergoing pilot testing starting in 2025.


The Medicover Endometriosis Center offers patients an integrated medical pathway: comprehensive diagnostic workup, longitudinal monitoring, personalized medical therapies, and/or minimally invasive surgical management (laparoscopy), tailored to each clinical scenario.



  1. Treatment of Endometriosis

Endometriosis is a chronic inflammatory disorder that evolves rhythmically with the menstrual cycle, spanning from menarche to menopause. It manifests in diverse clinical forms, often with poor correlation between lesion burden and symptom severity. These characteristics justify an individualized patient management strategy based on symptoms, anatomical lesion localization, pregnancy plans, as well as the risks and side effects of treatments.


Management of painful endometriosis can be purely pharmacological or combined with surgery. Infertility associated with endometriosis can be treated using medically assisted reproduction (ART) techniques and/or surgical intervention.


There is no definitive curative treatment for endometriosis.


Endometriosis can be managed either through surgical intervention or medical therapies, but most frequently through an integrated combination of both.


Because the precise etiopathogenesis of endometriosis remains incompletely elucidated, there is currently no targeted pharmacological therapy specifically directed against endometriotic stromal and epithelial cells.


  1. Medical Therapy for Endometriosis

Currently, the fundamental principle of medical management is inducing therapeutic amenorrhea using pharmacological agents that simulate either pregnancy or menopause (the two physiological states of anovulation and amenorrhea in a woman's reproductive life). In the vast majority of cases, this strategy arrests lesion progression and reduces pain symptoms, although it rarely leads to lesion eradication.


However, because it inhibits ovulation, medical therapy acts as a contraceptive and must be discontinued in women actively pursuing pregnancy.


Medical therapy aims to achieve amenorrhea and fulfills two primary objectives:

  • Alleviating painful symptoms by reducing local inflammation and providing analgesia (nonsteroidal anti-inflammatory drugs, stepped analgesic regimens);

  • Halting lesion progression by suppressing ovarian steroidogenesis (continuous hormonal regimens, such as combined oral contraceptives, progestin-only pills, synthetic progestins, GnRH agonists/antagonists).


Hormonal Therapies to Suppress Ovarian Function

  • They are effective in alleviating pain and can arrest lesion progression, provided they are administered continuously (without hormone-free intervals);

  • When administered postoperatively, they significantly reduce the rate of disease recurrence;

  • Conversely, they have an inherent contraceptive effect and may cause adverse effects leading to treatment discontinuation (breakthrough bleeding, weight gain, decreased libido, vaginal dryness, vasomotor hot flashes, etc.);

  • Upon discontinuation, lesion proliferation frequently resumes, and analgesic benefit is generally lost within a few months. For this reason, maintenance of therapy until natural menopause is often indicated.


  1. Surgical Treatment of Endometriosis

The goal of surgery is to excise or ablate endometriotic lesions, lysing adhesions and restoring normal anatomy to treat pain and improve fertility. Long-term postoperative amenorrhea helps prevent recurrence.

  • As a general rule, optimal outcomes are achieved when patients undergo a single, complete, well-executed surgery, avoiding iterative, incomplete interventions;


  • Excision or ablation (in situ destruction) of superficial peritoneal endometriosis is within the technical scope of most laparoscopic gynecological surgeons;


  • Excision (cystectomy) or ablation of ovarian endometriomas carries the risk of significantly reducing the ovarian reserve, with adverse consequences for fertility. The absence of a distinct histological cleavage plane between the pseudocyst capsule and normal ovarian parenchyma often leads to involuntary removal of healthy ovarian cortex. Repeated surgeries for recurrent endometriomas can result in premature ovarian insufficiency. For this reason, alternative approaches should be considered in bilateral endometriomas, recurrences, very large cysts, or low baseline ovarian reserve: endometrioma vaporization (plasma energy or CO2 laser ablation), sclerotherapy (ethanol instillation), or drainage;


  • Surgery for deep infiltrating endometriosis requires advanced surgical expertise, and it is strongly recommended that patients be referred to specialized tertiary centers. Depending on nodule topography, surgery may require complex multidisciplinary procedures involving the colorectal tract, urinary tract, sacral plexus, and diaphragm. The surgical indication must balance expected symptomatic relief against the risk of intra- and postoperative morbidity;


  • Postoperative recurrences can occur prior to menopause, particularly in patients who do not receive suppressive hormonal therapy and resume cyclic menses. A recurrence of pain does not automatically imply macroscopic lesion recurrence and does not necessarily warrant repeat surgery.


  • In select cases, surgery may be performed in postmenopausal women with residual fibrotic nodules that cause bowel obstruction, deep dyspareunia, or nerve entrapment. In such scenarios, menopause does not lead to complete regression of the fibrous component, which remains symptomatic despite the absence of hormonal stimulation.



Endometriosis Treatments in Figures

80%

of women operated on for colorectal endometriosis

conceive within 5 years after surgery

47-56%

of women operated on for colorectal endometriosis

are free of dysmenorrhea at 5 years postoperatively

66-72%

of women operated on for colorectal endometriosis

are free of dyspareunia at 5 years postoperatively


The specialist team at the IFEM Endo Medicover Cluj Endometriosis Center provides integrated diagnostic and therapeutic solutions. In addition, the Center ensures patients benefit from high-standard, comfortable inpatient facilities.


Frequently Asked Questions


1. How long does surgery for endometriosis take?


2. How long is the hospital stay?


3. Is postoperative bleeding normal?


4. How long does acute postoperative pain last?


5. Is it normal to experience different sensations of pain compared to preoperative pain?


6. What warning signs should prompt urgent evaluation during the first month following surgery?

Top Expertise for Women's Health


The IFEM Endo Medicover Cluj Endometriosis Center was established out of the need to provide patients with access to accurate diagnosis and personalized treatment based on the latest medical standards. Created in partnership with the IFEM Endo Institute, this center represents a first in the region, bringing together a multidisciplinary team of specialists dedicated to the integrated management of endometriosis.


Through the collaboration between Medicover Hospital Cluj and the IFEM Endo Institute, patients benefit from advanced technologies, internationally recognized expertise, and an individualized approach designed to improve the quality of life of women affected by this complex condition.


Request an Appointment

Appointments are made exclusively through the call center! After scheduling, please download and send the completed questionnaire to the email address: ifemendocluj@medicover.ro!



The Center's Mission

The Endometriosis Center of Medicover Hospital Cluj, in partnership with IFEM Endo, has the mission of providing excellent medical care to women diagnosed with endometriosis through a multidisciplinary, minimally invasive, and personalized approach. We are dedicated to improving patients' quality of life through accurate diagnosis, innovative treatments, and long-term support based on the latest international guidelines.


About Endometriosis

Endometriosis is a chronic disease in which tissue resembling endometrium is found outside the uterus.

These fragments are located inside the abdominal cavity, where they can graft onto the peritoneum, a thin membrane covering all intra-abdominal organs (peritoneal or superficial endometriosis), or beyond this membrane, deeply infiltrating various organs or anatomical structures (subperitoneal/deep infiltrating endometriosis).

These tissue fragments, known as "endometriotic lesions," vary in size (from a few tens of microns to several centimeters) and have the potential to grow and spread via foci that flare synchronously with menstruation.


What is the endometrium?


Causes of Endometriosis


Consequences of Endometriotic Lesions


Types of Endometriosis

From a didactic standpoint, endometriotic lesions are classified into 3 major groups, which may coexist in the same woman. Theoretically, endometriotic lesions can be found anywhere in the pelvis and abdomen and, more rarely, in the thorax.


  1. Superficial peritoneal lesions are likely the most common and are localized on the peritoneum.

These are small, superficial lesions whose invasion depth does not exceed 5 mm.

They can present in various forms:

  • Sometimes, they are active, red lesions, closely resembling endometrium, often hemorrhagic, surrounded by an inflammatory reaction (a);

  • Other lesions have a brownish appearance (b), or appear as black microcysts (c), indicating old hemorrhage;

  • Others are whitish and fibrotic, indicating a healing or cicatricial process (d).


  1. Cystic ovarian lesions (ovarian endometriomas)

These are hemorrhagic lesions that develop beneath the ovarian parenchyma and progressively displace it. Ranging in size from a few millimeters to several centimeters, these lesions are not true intra-ovarian cysts like other types of ovarian cysts. They are the result of intra-ovarian invagination of a lesion initially located on the ovarian surface, which gradually invaginates into the ovary. This characteristic makes surgical management difficult, as the endometrioma wall and the ovarian tissue are sometimes inseparable, which can lead to ovarian damage during cystectomy.


  1. Deep subperitoneal lesions (infiltration greater than 5 mm)

These are firm, fibrous lesions in which hormone-dependent endometrial tissue accounts for a relatively small proportion (15-20% of the endometriotic nodule volume). These lesions tend to infiltrate surrounding organs, behaving aggressively like tumors, resulting in severe presentations that become increasingly difficult to resect. Due to their fibrous composition, which is poorly hormone-dependent, the size of deep endometriotic nodules is minimally influenced by amenorrhea, which only stabilizes the disease but practically never causes it to regress completely. This explains why they can be found in postmenopausal women, where they may remain symptomatic despite definitive amenorrhea.


Symptoms of Endometriosis

Endometriotic lesions are responsible for a wide range of painful symptoms that initially occur during menstruation. Over the years, these symptoms may also present outside menses, though their severity remains highest during or around menstruation. Classic symptoms include lower abdominal pain (pelvic pain), deep pelvic pain during sexual intercourse (dyspareunia), pain with bowel movements (dyschezia) or urination (dysuria), chest or shoulder pain, and sciatica-type radiating pain. Endometriosis can also lead to infertility. This infertility, combined with the painful symptoms described above, justifies screening for endometriosis.


Dysmenorrhea (Painful Menstruation)


Deep Dyspareunia or Pain During Intercourse


Gastrointestinal symptoms associated with menstruation are varied and nonspecific


Urinary Symptoms


Other Catamenial Symptoms


Intermenstrual Pain


Infertility


Endometriosis Symptoms in Numbers

40%

of women suffering from infertility

and chronic pain have endometriosis

48%

report that their sexual life is impaired by the disease

45%

believe their professional career

has been adversely affected by this condition



  • Diagnosis of Endometriosis

The diagnosis of endometriosis is primarily clinical. An experienced practitioner can make the diagnosis in most cases well before performing imaging studies, guided by thorough clinical history-taking and a meticulous, focused physical examination.

The purpose of complementary examinations is to evaluate disease severity (staging/mapping of lesions) and to guide appropriate treatment planning. These must be performed by radiologists and sonographers experienced in endometriosis. Normal imaging does not rule out the diagnosis, especially in cases of superficial peritoneal endometriosis.


  • The Consultation

This is fundamental and often sufficient to establish clinical suspicion. The objective is to correlate the timeline of painful symptoms with the menstrual cycle. It must also screen for the symptoms mentioned above (pelvic pain, dyspareunia, gastrointestinal and urinary symptoms, etc.).


  • Abdominal Examination

Generally causes nonspecific tenderness (pain upon palpation of the colon frame or pelvis). However, when performed during an acute pain flare, it can mimic an acute surgical abdomen. In addition, rare complications can truly cause an acute surgical abdomen (bowel obstruction, renal colic).


  • Speculum Examination

Must be performed gently, as contact with the vaginal fornices is often painful. It is frequently normal, but may reveal a deep infiltrating nodule involving the posterior vaginal fornix, visible as a bluish/black microcystic lesion or fibrotic retraction.


  • Bimanual Vaginal Examination

It is essential, as it can confirm the presence of deep endometriosis, though it cannot be performed in virginal patients. Findings sought upon palpation include:

  • A soft but tender posterior vaginal fornix, which may indicate superficial endometriosis of the pouch of Douglas;

  • A palpable, tender nodule or induration in the vaginal fornices, indicative of deep infiltrating endometriosis;

  • An enlarged, globally tender uterus suggestive of adenomyosis;

  • A cystic adnexal mass suggestive of an ovarian endometrioma.


  • Digital Rectal Examination

It is particularly useful when deep retrocervical endometriosis is suspected and can be used to evaluate infiltration of the anterior rectal wall or parametria.


Paraclinical Examinations


  • Transvaginal Pelvic Ultrasound

Ultrasound is considered the first-line imaging modality and is highly accurate in the hands of an experienced radiologist or gynecologist. It can identify:

  • Ovarian endometriomas;

  • Adenomyosis;

  • Deep infiltrating endometriosis nodules in the uterosacral ligaments, bladder, rectum, and distal sigmoid colon;

  • Pelvic cystic collections, such as dilated fallopian tubes filled with blood (hematosalpinx), peritoneal pseudocysts resulting from adhesions, etc.


  • Abdominal Ultrasound

Can be used to detect complications of endometriosis, such as ureteral stenosis with hydronephrosis, renal atrophy, or extensive intra-abdominal endometriosis with ascites formation, etc.


  • Magnetic Resonance Imaging (MRI)

Pelvic MRI is an exceptional diagnostic modality that allows not only diagnosis but also precise anatomical mapping of intrapelvic and intra-abdominal endometriotic lesions. In our practice, it is virtually indispensable prior to surgical intervention and allows detection of:

  • Ovarian endometriomas containing blood products, which display characteristic hyperintensity on T1-weighted fat-saturated sequences and hypointensity on T2-weighted sequences ("T2 shading");

  • Deep endometriotic nodules presenting as stellate (hypointense on T1 and T2), retractile tissue infiltrating adjacent organs (rectum, sigmoid colon, vagina, bladder, etc.), sometimes containing hemorrhagic microcysts;

  • Adenomyosis, confirmed by junctional zone thickening or multiple myometrial hyperintense microspots;

  • Complications of endometriosis (hematosalpinx, ureteral stenosis with hydronephrosis, infiltration of parametria or sacral roots, digestive tract stenosis, etc.).


Other investigations may be indicated in severe cases, depending on the anatomical sites of endometriotic lesions identified on ultrasound and MRI.


These include endorectal ultrasound and CT colonography in cases of colorectal endometriosis, cystoscopy, CT urography or MR urography in urinary tract involvement, and MRI and/or CT of the diaphragm for diaphragmatic endometriosis. No serum biomarker is disease-specific. Elevated CA-125 may be observed in cases of ovarian or extensive peritoneal endometriosis, but this non-specific test is not routinely indicated.


Currently, research is ongoing to identify serum biomarkers that could reliably detect whether a woman has endometriosis via a simple blood test.


  • Laparoscopy

If necessary, a definitive histopathological diagnosis can be obtained by exploratory laparoscopy combined with targeted biopsy and pathological examination.


In cases of infertility, it can be used to stage prognosis according to the rASRM classification (revised American Society for Reproductive Medicine) and, when appropriate, treat superficial lesions.


However, diagnostic laparoscopy is not mandatory to initiate medical therapy in patients where endometriosis is strongly suspected on clinical examination and non-invasive imaging. It should be reserved for cases with diagnostic uncertainty and is not recommended solely to confirm conclusive imaging findings.


Today, laparoscopy is primarily reserved for therapeutic surgical management of endometriotic lesions.



  • Saliva Test

A major breakthrough in the field of endometriosis has been the introduction, in 2022, of a salivary biomarker test for endometriosis. Developed based on the scientific research of Professor Bendifallah and manufactured by the French biotech company ZIWIG, this saliva test boasts high diagnostic sensitivity and specificity, enabling the distinction between women with and without endometriosis with a low error rate.


The test identifies an expression signature composed of 109 microRNAs, developed through the combination of next-generation sequencing and artificial intelligence, and was evaluated in two prospective clinical studies (monocentric and multicentric). This diagnostic tool is promising and paves the way for advanced non-invasive testing capable of predicting specific endometriosis subtypes, allowing personalized therapeutic and monitoring strategies tailored to the progressive risk of each phenotype, similar to paradigms established in breast oncology.


The exact clinical positioning of the saliva test relative to imaging modalities has yet to be definitively formalized by the French National Authority for Health (HAS), though reimbursement coverage by the French health insurance system (CPAM) is undergoing pilot testing starting in 2025.


The Medicover Endometriosis Center offers patients an integrated medical pathway: comprehensive diagnostic workup, longitudinal monitoring, personalized medical therapies, and/or minimally invasive surgical management (laparoscopy), tailored to each clinical scenario.



  1. Treatment of Endometriosis

Endometriosis is a chronic inflammatory disorder that evolves rhythmically with the menstrual cycle, spanning from menarche to menopause. It manifests in diverse clinical forms, often with poor correlation between lesion burden and symptom severity. These characteristics justify an individualized patient management strategy based on symptoms, anatomical lesion localization, pregnancy plans, as well as the risks and side effects of treatments.


Management of painful endometriosis can be purely pharmacological or combined with surgery. Infertility associated with endometriosis can be treated using medically assisted reproduction (ART) techniques and/or surgical intervention.


There is no definitive curative treatment for endometriosis.


Endometriosis can be managed either through surgical intervention or medical therapies, but most frequently through an integrated combination of both.


Because the precise etiopathogenesis of endometriosis remains incompletely elucidated, there is currently no targeted pharmacological therapy specifically directed against endometriotic stromal and epithelial cells.


  1. Medical Therapy for Endometriosis

Currently, the fundamental principle of medical management is inducing therapeutic amenorrhea using pharmacological agents that simulate either pregnancy or menopause (the two physiological states of anovulation and amenorrhea in a woman's reproductive life). In the vast majority of cases, this strategy arrests lesion progression and reduces pain symptoms, although it rarely leads to lesion eradication.


However, because it inhibits ovulation, medical therapy acts as a contraceptive and must be discontinued in women actively pursuing pregnancy.


Medical therapy aims to achieve amenorrhea and fulfills two primary objectives:

  • Alleviating painful symptoms by reducing local inflammation and providing analgesia (nonsteroidal anti-inflammatory drugs, stepped analgesic regimens);

  • Halting lesion progression by suppressing ovarian steroidogenesis (continuous hormonal regimens, such as combined oral contraceptives, progestin-only pills, synthetic progestins, GnRH agonists/antagonists).


Hormonal Therapies to Suppress Ovarian Function

  • They are effective in alleviating pain and can arrest lesion progression, provided they are administered continuously (without hormone-free intervals);

  • When administered postoperatively, they significantly reduce the rate of disease recurrence;

  • Conversely, they have an inherent contraceptive effect and may cause adverse effects leading to treatment discontinuation (breakthrough bleeding, weight gain, decreased libido, vaginal dryness, vasomotor hot flashes, etc.);

  • Upon discontinuation, lesion proliferation frequently resumes, and analgesic benefit is generally lost within a few months. For this reason, maintenance of therapy until natural menopause is often indicated.


  1. Surgical Treatment of Endometriosis

The goal of surgery is to excise or ablate endometriotic lesions, lysing adhesions and restoring normal anatomy to treat pain and improve fertility. Long-term postoperative amenorrhea helps prevent recurrence.

  • As a general rule, optimal outcomes are achieved when patients undergo a single, complete, well-executed surgery, avoiding iterative, incomplete interventions;


  • Excision or ablation (in situ destruction) of superficial peritoneal endometriosis is within the technical scope of most laparoscopic gynecological surgeons;


  • Excision (cystectomy) or ablation of ovarian endometriomas carries the risk of significantly reducing the ovarian reserve, with adverse consequences for fertility. The absence of a distinct histological cleavage plane between the pseudocyst capsule and normal ovarian parenchyma often leads to involuntary removal of healthy ovarian cortex. Repeated surgeries for recurrent endometriomas can result in premature ovarian insufficiency. For this reason, alternative approaches should be considered in bilateral endometriomas, recurrences, very large cysts, or low baseline ovarian reserve: endometrioma vaporization (plasma energy or CO2 laser ablation), sclerotherapy (ethanol instillation), or drainage;


  • Surgery for deep infiltrating endometriosis requires advanced surgical expertise, and it is strongly recommended that patients be referred to specialized tertiary centers. Depending on nodule topography, surgery may require complex multidisciplinary procedures involving the colorectal tract, urinary tract, sacral plexus, and diaphragm. The surgical indication must balance expected symptomatic relief against the risk of intra- and postoperative morbidity;


  • Postoperative recurrences can occur prior to menopause, particularly in patients who do not receive suppressive hormonal therapy and resume cyclic menses. A recurrence of pain does not automatically imply macroscopic lesion recurrence and does not necessarily warrant repeat surgery.


  • In select cases, surgery may be performed in postmenopausal women with residual fibrotic nodules that cause bowel obstruction, deep dyspareunia, or nerve entrapment. In such scenarios, menopause does not lead to complete regression of the fibrous component, which remains symptomatic despite the absence of hormonal stimulation.



Endometriosis Treatments in Figures

80%

of women operated on for colorectal endometriosis

conceive within 5 years after surgery

47-56%

of women operated on for colorectal endometriosis

are free of dysmenorrhea at 5 years postoperatively

66-72%

of women operated on for colorectal endometriosis

are free of dyspareunia at 5 years postoperatively


The specialist team at the IFEM Endo Medicover Cluj Endometriosis Center provides integrated diagnostic and therapeutic solutions. In addition, the Center ensures patients benefit from high-standard, comfortable inpatient facilities.


Frequently Asked Questions


1. How long does surgery for endometriosis take?


2. How long is the hospital stay?


3. Is postoperative bleeding normal?


4. How long does acute postoperative pain last?


5. Is it normal to experience different sensations of pain compared to preoperative pain?


6. What warning signs should prompt urgent evaluation during the first month following surgery?

Find our location here:

323T Principală Street, Suceagu

The team at

The team at

IFEMEndo Endometriosis Center

IFEMEndo Endometriosis Center